We have shown that tumour promoter methylation within our target suppressor gene panel is commonly observed in familial and particularly BRCA2 male breast cancers suggesting aberrant hypermethylation may be a significant driver in MBCs carrying prognostic information. The gene discussed is BRCA2; the disease is maternal uniparental disomy of chromosome 20.